

Muse Treatment Publishes New Neurofeedback Resource Following 2026 Addiction Research and Changing Overdose Trends

September 14, 2026

LOS ANGELES, CA - September 14, 2026 -
Muse Treatment has published a new educational resource examining neurofeedback therapy and its developing role in substance use disorder treatment. The article, ?What Is Neurofeedback Therapy for Addiction,? explains how neurofeedback uses real-time information about brain activity to help patients practice self-regulation and describes how the approach may be incorporated alongside established behavioral and medical treatment rather than used as a stand-alone intervention.

The publication follows new research that has expanded the evidence available on neurofeedback for addiction. A systematic review and meta-analysis published in the journal Addiction in February 2026 evaluated 17 randomized controlled trials involving 662 participants. Researchers found statistically significant improvements in addiction-related symptoms among patients receiving EEG neurofeedback, with particularly encouraging findings for substance-related disorders. The researchers also reported substantial differences among study populations and treatment protocols, identifying standardization and further research as continuing priorities.

Those findings build on a separate 2025 systematic review published in Psychiatry Research. That analysis examined 32 studies involving EEG, functional MRI, and functional near-infrared spectroscopy neurofeedback. Researchers reported reductions in drug craving and improvements in some mental health measures while concluding that neurofeedback currently shows the most support as an adjunctive intervention rather than a replacement for established substance use disorder treatment.

The timing also coincides with changing substance-related public health trends in Los Angeles County. In June 2026, the Los Angeles County Department of Public Health reported that drug-related overdose and poisoning deaths had declined for a third consecutive year. Deaths decreased 6 percent from 2024 to 2025, including a 10 percent reduction in fentanyl-related deaths and a 7 percent decline in methamphetamine-related deaths. County health officials attributed the trend to combined prevention, harm-reduction, treatment and recovery efforts while continuing to emphasize access to behavioral health services.

Against that research and public-health backdrop, the new Muse Treatment resource explains how neurofeedback works in a clinical setting. Sensors are used to monitor brain activity while software provides feedback that allows patients to observe patterns associated with attention, stress response, and emotional regulation. The process is designed to help patients practice regulating those patterns over repeated sessions.

Current research does not establish neurofeedback as an appropriate intervention for every patient. The 2026 meta-analysis reported promising results but also noted heterogeneity among studies, whereas the 2025 systematic review identified meaningful differences in neurofeedback methods and treatment protocols. Presenting those limitations alongside potential benefits is important for patients considering therapies that remain under active investigation.

Muse Treatment?s published Los Angeles treatment information places neurofeedback within a wider continuum of addiction care rather than presenting it as an isolated service. The organization describes medically supervised detoxification, residential treatment, outpatient programming and intensive outpatient treatment, along with services for co-occurring mental health conditions. Behavioral approaches described by the provider include cognitive behavioral therapy, dialectical behavior therapy, trauma-informed care, medication management, relapse-prevention planning and family therapy.

Independent certification provides an additional reference point for evaluating the organization. CARF International currently lists A New Start Treatment and Recovery, LLC, doing business as Muse Treatment, as certified for ASAM Level of Care 3.7 for adults at its Culver City locations. CARF?s listing independently

verifies that defined level of substance use disorder care without relying on promotional claims from the provider. Certification does not predict a particular patient outcome, but it gives patients and referral professionals an external standard to consider when reviewing treatment programs.

The organization?s Westwood location also provides outpatient treatment. Muse currently identifies its intensive outpatient program at 1251 Westwood Boulevard, while its Culver City facilities are associated with higher-intensity treatment services. The distinction is relevant because addiction treatment needs can change as patients progress from medical stabilization or residential care toward outpatient-based support.

For people conducting a drug rehab near me search in Los Angeles, the new resource offers another clinical factor to consider beyond proximity. Treatment decisions may depend on withdrawal risk, psychiatric symptoms, medical stability, available levels of care, and whether newer interventions such as neurofeedback are used as part of a broader evidence-informed treatment plan.

People using search terms such as best drug rehab centers, inpatient drug rehab, outpatient drug rehab, and intensive outpatient drug rehab (IOP) may encounter programs with substantially different clinical capabilities. Independent certification, treatment intensity, medical oversight, psychiatric services and continuity between residential and outpatient care provide more objective criteria for comparing those options than generalized rankings.

The resource may have particular relevance for patients and families in Westwood, Westwood Village, Little Holmby and Holmby Hills who are evaluating addiction treatment in the surrounding Los Angeles area. Geographic convenience can influence transportation, family participation and continued outpatient attendance, but proximity alone does not establish whether a program or therapy is clinically appropriate.

California also maintains separate oversight of residential and outpatient substance use disorder treatment. The California Department of Health Care Services states that it has sole authority to license adult residential alcohol and drug treatment facilities and to certify and monitor outpatient substance use disorder programs. DHCS licensing requirements provide another framework patients can use when evaluating treatment settings alongside independent accreditation or certification.

Neurofeedback research remains an evolving area of addiction medicine. The recent meta-analysis provides stronger evidence than was available several years ago, but researchers continue to call for more consistent protocols and additional controlled studies. That scientific context makes careful communication important, particularly when emerging therapies are discussed with patients who may be weighing multiple treatment options.

By publishing the new resource, Muse Treatment is adding an explanatory patient resource to a broader 2026 discussion shaped by new neurofeedback research and changing overdose trends in Los Angeles County. The article outlines how the therapy works, where it may fit within addiction treatment, and why emerging neuroscience-based approaches should be evaluated alongside established behavioral health services, appropriate levels of care, and independent clinical standards.

###

For more information about Muse Treatment, contact the company here:Muse TreatmentDavid Rofofsky(800) 426-1818info@musetreatment.com1251 Westwood Blvd, Los Angeles, CA 90024

Muse Treatment

Muse Treatment is the #1 addiction treatment center in Los Angeles, California for alcohol, prescription and drug rehab as well as detox.

Website: https://musetreatment.com/

Email: info@musetreatment.com

Phone: (800) 426-1818